| Literature DB >> 29695923 |
Elena De Vecchi1, David A George2, Carlo L Romanò3, Fabrizio E Pregliasco4,5, Roberto Mattina6, Lorenzo Drago1,4.
Abstract
INTRODUCTION: Coagulase-negative staphylococci (CoNS) are the main pathogens responsible for prosthetic joint infections (PJIs). As normal inhabitants of human skin, it is often difficult to define if they are contaminants, or if they have an active role in initiating infection. This study aims to evaluate differences in CoNS organisms (Staphylococcus hominis, Staphylococcus capitis, Staphylococcus haemolyticus, Staphylococcus warneri) and Staphylococcus aureus in terms of isolation rate and antimicrobial susceptibility from patients who met the International Consensus Meeting (ICM) criteria for PJIs and those who did not.Entities:
Keywords: Staphylococcus aureus; Staphylococcus capitis; Staphylococcus haemolyticus; Staphylococcus hominis; Staphylococcus warneri; antibiotics susceptibility; periprosthetic joint infections
Year: 2018 PMID: 29695923 PMCID: PMC5905490 DOI: 10.2147/IDR.S151271
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Pathogens isolated in each patient cohort
| Group A | Group B | |||
|---|---|---|---|---|
|
|
| |||
| n | % | n | % | |
| 19 | 21.3 | 6 | 30 | |
| 14 | 15.7 | 6 | 30 | |
| 11 | 12.4 | 3 | 15 | |
| 6 | 6.7 | 1 | 5.0 | |
| 39 | 43.8 | 4 | 20 | |
| Total | 89 | 100 | 20 | 100 |
Characteristics of patients of Group A and Group B
| Characteristics | Group A | Group B | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
| ||||||
| CoNS (n=50) | CoNS (n=16) | Group A vs Group B | ||||||
|
| ||||||||
| n | n | n | n | Group A | Group B | CoNS | ||
| Gender | Male | 20 | 23 | 1 | 9 | 0.150 | 0.248 | 0.176 |
| Female | 19 | 27 | 3 | 7 | ||||
| Age (years) | Mean (SD) | 65.7 (13.9) | 65.0 (12.3) | 55.5 (17.8) | 61.3 (16.3) | 0.810 | 0.557 | 0.327 |
| Range | 30–85 | 29–84 | 31–71 | 19–87 | ||||
| Joint | Hip | 24 | 26 | 3 | 9 | 0.126 | 0.331 | 0.221 |
| Knee | 15 | 23 | 1 | 8 | ||||
| ESR (mm/hr) | Mean (SD) | 58.6 (25) | 34.5 (24.5) | 24.5 (/17.8) | 24.5 (17.8) | 0.002 | 0.266 | 0.209 |
| >30 mm/hr | 28 | 20 | 0 | 4 | 0.016 | 0.484 | 0.202 | |
| Range | 5–100 | 7–99 | 3–26 | 5–55 | ||||
| CRP (mg/L) | Mean (SD) | 52.4 (51.5) | 28.3 (3.65) | 2.18 (1.45) | 3.07 (2.7) | 0.087 | 0.536 | 0.174 |
| >10 mg/L | 34 | 26 | 0 | 0 | <0.001 | 1.000 | <0.011 | |
| Range | 3.2–255 | 0.5–485 | 0.3–3.5 | 0.8–9.9 | ||||
Abbreviations: CoNS, coagulase-negative staphylococci; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
Susceptibility of staphylococci isolated from patients fulfilling PJI criteria (group A)
| Antibiotic | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
| |||||||||||
| S | I | R | S | I | R | S | I | R | S | I | R | S | I | R | |
| Fusidic acid | 16 | 0 | 3 | 10 | 0 | 4 | 11 | 0 | 0 | 4 | 0 | 2 | 37 | 0 | 2 |
| Clindamycin | 16 | 0 | 3 | 7 | 0 | 7 | 11 | 0 | 0 | 3 | 0 | 3 | 29 | 0 | 10 |
| Daptomycin | 15 | 0 | 4 | 14 | 0 | 0 | 10 | 0 | 1 | 6 | 0 | 0 | 39 | 0 | 0 |
| Erythromycin | 14 | 0 | 5 | 2 | 0 | 12 | 9 | 0 | 2 | 0 | 0 | 6 | 24 | 1 | 14 |
| Gentamicin | 18 | 0 | 1 | 5 | 0 | 9 | 8 | 0 | 3 | 1 | 0 | 5 | 33 | 0 | 6 |
| Levofloxacin | 17 | 0 | 2 | 10 | 0 | 4 | 11 | 0 | 0 | 1 | 0 | 5 | 23 | 0 | 16 |
| Linezolid | 19 | 0 | 0 | 14 | 0 | 0 | 11 | 0 | 0 | 6 | 0 | 0 | 39 | 0 | 0 |
| Oxacillin | 11 | 0 | 8 | 6 | 0 | 8 | 9 | 0 | 2 | 1 | 0 | 5 | 27 | 0 | 12 |
| Rifampicin | 19 | 0 | 0 | 14 | 0 | 0 | 10 | 0 | 1 | 2 | 0 | 4 | 27 | 1 | 11 |
| Teicoplanin | 19 | 0 | 0 | 14 | 0 | 0 | 11 | 0 | 0 | 6 | 0 | 0 | 38 | 0 | 1 |
| Tetracycline | 18 | 0 | 0 | 6 | 2 | 6 | 8 | 1 | 2 | 1 | 2 | 3 | 29 | 1 | 9 |
| Tigecycline | 19 | 0 | 0 | 14 | 0 | 0 | 11 | 0 | 0 | 6 | 0 | 0 | 39 | 0 | 0 |
| Trimethoprim/sulfamethoxazole | 18 | 0 | 1 | 12 | 2 | 0 | 11 | 0 | 0 | 3 | 0 | 3 | 37 | 0 | 2 |
| Vancomycin | 19 | 0 | 0 | 14 | 0 | 0 | 11 | 0 | 0 | 6 | 0 | 0 | 39 | 0 | 0 |
Abbreviations: PJI, prosthetic joint infection; S, susceptible; I, intermediate; R, resistant.
Susceptibility of staphylococci isolated from patients not fulfilling PJI criteria (group B)
| Antibiotic | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
| |||||||||||
| S | I | R | S | I | R | S | I | R | S | I | R | S | I | R | |
| Fusidic acid | 5 | 0 | 1 | 4 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 1 |
| Clindamycin | 6 | 0 | 0 | 5 | 0 | 1 | 3 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 3 |
| Daptomycin | 6 | 0 | 0 | 6 | 0 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0 |
| Erythromycin | 6 | 0 | 0 | 4 | 0 | 2 | 2 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 3 |
| Gentamicin | 6 | 0 | 0 | 4 | 0 | 2 | 2 | 0 | 1 | 1 | 0 | 0 | 3 | 0 | 1 |
| Levofloxacin | 6 | 0 | 0 | 6 | 0 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 2 |
| Linezolid | 6 | 0 | 0 | 6 | 0 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0 |
| Oxacillin | 5 | 0 | 1 | 5 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 2 |
| Rifampicin | 6 | 0 | 0 | 6 | 0 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0 |
| Teicoplanin | 6 | 0 | 0 | 6 | 0 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0 |
| Tetracycline | 4 | 2 | 0 | 4 | 2 | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 3 | 0 | 1 |
| Tigecycline | 6 | 0 | 0 | 6 | 0 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0 |
| Trimethoprim/sulfamethoxazole | 6 | 0 | 0 | 6 | 0 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0 |
| Vancomycin | 6 | 0 | 0 | 6 | 0 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0 |
Abbreviations: PJI, prosthetic joint infection; S, susceptible; I, intermediate; R, resistant.
Comparison of CoNS in Group A and B
| Antibiotic | Group A | Group B | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
| ||||||||
| Susceptible | Not susceptible | Susceptible | Not susceptible | ||||||
|
|
|
|
| ||||||
| Fusidic acid | 41 | 82 | 9 | 18 | 12 | 75 | 4 | 25 | 0.540 |
| Clindamycin | 37 | 74 | 13 | 26 | 15 | 94 | 1 | 6 | 0.093 |
| Daptomycin | 45 | 90 | 5 | 10 | 16 | 100 | 0 | 0 | 0.086 |
| Erythromycin | 25 | 50 | 25 | 50 | 12 | 75 | 4 | 25 | 0.079 |
| Gentamicin | 32 | 64 | 18 | 36 | 13 | 81 | 3 | 19 | 0.197 |
| Levofloxacin | 39 | 78 | 11 | 22 | 16 | 100 | 0 | 0 | 0.009 |
| Linezolid | 50 | 100 | 0 | 0 | 16 | 100 | 0 | 0 | 1.000 |
| Oxacillin | 27 | 54 | 23 | 46 | 13 | 81 | 3 | 19 | 0.052 |
| Rifampicin | 45 | 90 | 5 | 10 | 16 | 100 | 0 | 0 | 0.086 |
| Teicoplanin | 50 | 100 | 0 | 0 | 16 | 100 | 0 | 0 | 1.000 |
| Tetracycline | 33 | 66 | 17 | 34 | 10 | 63 | 6 | 38 | 0.798 |
| Tigecycline | 50 | 100 | 0 | 0 | 16 | 100 | 0 | 0 | 1.000 |
| Trimethoprim/sulfamethoxazole | 44 | 88 | 6 | 12 | 16 | 100 | 0 | 0 | 0.059 |
| Vancomycin | 50 | 100 | 0 | 0 | 16 | 100 | 0 | 0 | 1.000 |
Abbreviation: CoNS, coagulase negative staphylococci.